Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the <scp>OGA</scp> Inhibitor <scp>ASN90</scp> in Healthy Participants
The phase 1 results of ASN90 in healthy participants provide strong support for its further development in progressive supranuclear palsy (PSP) and AD. Currently, Ferrer Internacional, S.A. is conducting a phase 2 study, known as PROSPER (ClinicalTrials.gov ID: NCT06355531), to evaluate the efficacy, safety, and pharmacokinetics of ASN90 in slowing the progression of PSP. © 2025 International Parkinson and Movement Disorder Society.
Authors
- Eugenii A. Rabiner (ORCID: https://orcid.org/0000-0003-3612-6687)
- Khalid Abd‐Elaziz (ORCID: https://orcid.org/0000-0002-0964-4940)
- Graham E. Searle (ORCID: https://orcid.org/0000-0001-6923-7645)
- Dirk Beher (ORCID: https://orcid.org/0000-0001-8005-5359)
- Christoph Wießner
- Bruno Permanne
- Anna Quattropani
- Rolf Pokorny (ORCID: https://orcid.org/0000-0002-3681-6007)
- Frans van den Berg (ORCID: https://orcid.org/0000-0002-3166-3910)
- J. Michael Ryan
- Manfred Schneider
- Jean‐François Stallaert
Institutions
- Wellcome Centre for Human Neuroimaging (GB)
- King's College London (GB)
- Hammersmith Hospital (GB)
- Hammersmith Medicines Research (GB)
- Invicro (United Kingdom) (GB)
- QPS (Netherlands) (NL)
- Asceneuron (Switzerland) (CH)
- Imperial College London (GB)
- École Polytechnique Fédérale de Lausanne (CH)
Publication Details
- Journal
- Movement Disorders
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1002/mds.70104
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00